Clinical trial
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck…
NCT00485485 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00485485 |
|---|---|
| Title | Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer |
| Official title | Phase II Study of Imatinib Mesylate and Docetaxel in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Squamous Cell Cancer |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate, Docetaxel |
| Enrollment | 7 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Jun 13, 2007 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: